As life science companies expand across multiple jurisdictions, decisions about where and how to structure your company’s operations can carry significant implications for IP strategy, regulatory oversight, corporate exposure and competition risk.
This session will examine the core legal and strategic considerations underpinning entry into new international life science markets, with a focus on the key IP, regulatory and commercial risks across major jurisdictions and how companies can align their operations across borders.
-Which IP, regulatory and commercial legal risks should drive jurisdiction selection when expanding life science operations internationally?
- How should companies structure corporate entities, IP ownership and licensing agreements when entering regulated pharmaceutical markets?
- How should companies manage competition law, pricing and market access risk when expanding internationally?
- What governance frameworks are needed to manage legal exposure on a global scale and ensure coordination between corporate, regulatory and IP teams?
Cornelia Keller
